showed that anti-EGFR CAR T cell migration to lung cancer site was enhanced by overexpression of CCR6, which recognizes lung cancer-produced CCL20, a chemokine that is highly expressed by lung adenocarcinoma cells. The gene discussed is CCR6; the disease is lung carcinoma.